Within the non-CAD cohort (n = 30; No CAD = 6, CAD = 24), we found that the mitochondrial-antioxidant genes AIFM2 (mean fold change difference: 0.78 ± 0.27, CI: 0.24 to 1.33, p < 0.01), TXNRD1 (mean fold change difference: 0.39 ± 0.17, CI: 0.05 to 0.73, p < 0.05), CAT (mean fold change difference: 0.46 ± 0.20, CI: 0.05 to 0.86, p < 0.05), PRDX3 (mean fold change difference: 0.29 ± 0.13, CI: 0.02 to 0.55, p < 0.05) and PRDX6 (mean fold change difference: 0.21 ± 0.10, CI: 0.01 to 0.40, p < 0.05) were significantly upregulated when MPO was expressed (Figure 4A–E). This evidence concerns the gene AIFM2 and coronary artery disorder.